Tripuraneni Radhika

SEC source: 0001193125-26-355735 · ownership.xml · derivative · entry 2

Tripuraneni Radhika · CIK 0001761114 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2034-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested.

SEC source: 0001193125-26-355735 · ownership.xml · nonDerivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001761114-26-000004 · primarydocument.xml · derivative · entry 7

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,697 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001761114-26-000004 · primarydocument.xml · derivative · entry 6

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,000 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001761114-26-000004 · primarydocument.xml · derivative · entry 5

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,000 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001761114-26-000004 · primarydocument.xml · derivative · entry 4

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,676 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001761114-26-000004 · primarydocument.xml · derivative · entry 3

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,657 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001761114-26-000004 · primarydocument.xml · derivative · entry 2

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 45,000 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001761114-26-000004 · primarydocument.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 64,000 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001193125-26-092028 · ownership.xml · derivative · entry 2

Tripuraneni Radhika · CIK 0001761114 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,150

Underlying: Common Stock · 19,150 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001193125-26-092028 · ownership.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,800

Underlying: Common Stock · 95,800 shares

Expires 2036-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

SEC source: 0001761114-26-000002 · primarydocument.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,697

Underlying: Common Stock · 1,697 shares

Expires 2036-01-31

F1 · shares: This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $45,000 for 2026.

F2 · derivative.exercise_date: The option will vest as to 1/12th of the total shares subject thereto on each monthly anniversary measured from January 1, 2026, such that 100% of the shares subject to the option will be fully vested on January 1, 2027.

SEC source: 0001562180-25-004760 · primarydocument.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2035-06-10

F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant.

SEC source: 0000950170-25-038004 · ownership.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 310,700

Underlying: Common Stock · 310,700 shares

Expires 2035-03-10

F1 · derivative.exercise_date: The option vests as to 25% on March 10, 2026 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001562180-25-000857 · primarydocument.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,657

Underlying: Common Stock · 10,657 shares

Expires 2035-01-31

F1 · shares: This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $40,000 for 2025.

F2 · derivative.exercise_date: The option will vest as to 1/12th of the total shares subject thereto on each monthly anniversary measured from January 1, 2025, such that 100% of the shares subject to the option will be fully vested on January 1, 2026.

SEC source: 0001562180-24-005550 · primarydocument.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,676

Underlying: Common Stock · 4,676 shares

Expires 2034-06-30

F1 · shares: This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $20,000 for the third and fourth quarters of 2024.

F2 · derivative.exercise_date: The option will vest as to 1/6th of the total shares subject thereto on each monthly anniversary of the date of grant, such that 100% of the shares subject to the option will be fully vested on January 1, 2025.

SEC source: 0001562180-24-005106 · primarydocument.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-06-09

F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant.

SEC source: 0001562180-23-005172 · primarydocument.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2033-06-11

F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant.

SEC source: 0001562180-22-005766 · primarydocument.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,000

Underlying: Common Stock · 64,000 shares

Expires 2032-07-25

F1 · derivative.exercise_date: 1/3rd of the shares subject to the option vest on the first anniversary measured from July 26, 2022 (the "Vesting Commencement Date"), and 1/36th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date.

SEC source: 0001140361-22-006893 · form4.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Ordinary Shares · 50,000 shares

Expires 2032-02-23

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 23, 2023 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0001567619-21-005085 · doc1.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,000

Underlying: Ordinary Shares · 56,000 shares

Expires 2031-02-25

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 25, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0001567619-21-004314 · doc1.xml · derivative · entry 2

Tripuraneni Radhika · CIK 0001761114 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,037

Underlying: Ordinary Shares · 37,037 shares

Expires 2028-04-02

F2 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 50,000 of the issuer's ordinary shares granted to the reporting person on April 2, 2018. In exchange, the reporting person received a replacement option, for 37,037 ordinary shares, having an exercise price of $22.85 per ordinary share.

F3 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 46/48 of the total number of shares subject to the option on the one year anniversary of the date of grant, with respect to 1/48 of the total number of shares subject to the option on March 2, 2022 and with respect to 1/48 of the total number of shares subject to the option on April 2, 2022, subject to the reporting person's continued service with the issuer on each such vesting date.

SEC source: 0001567619-21-004314 · doc1.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 50,000 shares

Expires 2028-04-02

F2 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 50,000 of the issuer's ordinary shares granted to the reporting person on April 2, 2018. In exchange, the reporting person received a replacement option, for 37,037 ordinary shares, having an exercise price of $22.85 per ordinary share.

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 2, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0001567619-20-005021 · doc1.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Ordinary Shares · 70,000 shares

Expires 2030-02-25

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 25, 2021 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0000899243-19-005423 · doc4.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Ordinary Shares · 50,000 shares

Expires 2029-02-27

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0000899243-18-030857 · doc4.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Ordinary Shares · 35,000 shares

Expires 2028-12-11

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on December 11, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.